April ended with procurement, not product demos, deciding who gets clinical access. NSW Health’s Single Digital Patient Record on Epic hosted by AWS, Telstra Health’s cloud spine, the TGA’s PCCP draft and Healthdirect’s clinician‑led procurement rules together mean vendors must prove cloud readiness, FHIR or HL7 interoperability, continuous update controls and auditable AI logs to win large contracts.

AI as procurement

Healthdirect’s new procurement rules plus TGA scrutiny and a review of roughly 200 ambient scribe offerings turned AI governance into a contract condition. MEDITECH’s live note capture, NiCE’s Epic Copilot work and Faz’s MedTalk AI pilot embedding an AI scribe into Epic made on‑device or tightly integrated scribes the default ask. Winners: large EMR vendors and cloud platform partners with governance teams and monitoring pipelines. Losers: small EMR and app vendors that cannot supply immutable logs, clinician accountability clauses or post‑launch surveillance. Executives must choose now between building continuous update processes or being shut out of public and enterprise tenders.

Cloud and scale

Telstra Health’s cloud native platform, Oracle’s Sydney AI Centre and NSW’s SDPR deployment across 17 districts shifted buying power to cloud providers and consolidated platforms. Canberra’s Anthropic agreement and MRFF funding talk further concentrate early AI validation at universities and big hospitals. Practical consequence: procurement shortlists will favour FHIR‑capable, identity‑capable vendors that can handle high transaction volumes and consent management. That raises switching costs and hands leverage to incumbents while squeezing niche vendors that still run on desktop‑first stacks.

Caution and constraint

Policy and operational realities set visible limits. Tighter PBS and PBAC rules for GLP‑1s and new TGA approvals like Wegovy force immediate prescribing workflow changes and eligibility checks in clinical software. Funding moves such as the $588.5 million Mental Health Check‑In LiCBT programme and Arexvy immunisation grants create demand but also raise expectations for reporting and real‑time capture. Equity is at stake: Illumina’s New Zealand onshore sequencing pilot and NSW RNA manufacturing commitments show domestic capacity matters. Failure modes to watch: underfunded vendors drowning in regulatory work, poor post‑deployment monitoring, and rural services being left without the identity and connectivity investments needed to use these tools.